Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Laura Jeanbart"'
Autor:
Melody A. Swartz, Jeffrey A. Hubbell, Pedro Romero, Patricia Corthésy, Alexandre de Titta, Marie Ballester, Laura Jeanbart
PDF file - 22K, As the tumor progresses, OVA expression decreases in the tumor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c6c0ff0a2a74b55f32572f9d07b269d
https://doi.org/10.1158/2326-6066.22538803.v1
https://doi.org/10.1158/2326-6066.22538803.v1
Autor:
Melody A. Swartz, Jeffrey A. Hubbell, Pedro Romero, Patricia Corthésy, Alexandre de Titta, Marie Ballester, Laura Jeanbart
PDF file - 23K, Targeting the tdLN with NP-TRP-2 + free CpG is therapeutically more beneficial than targeting a non-tdLN.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ea82d0907df110dcc9298adafb68adb
https://doi.org/10.1158/2326-6066.22538812.v1
https://doi.org/10.1158/2326-6066.22538812.v1
Autor:
Melody A. Swartz, Jeffrey A. Hubbell, Pedro Romero, Patricia Corthésy, Alexandre de Titta, Marie Ballester, Laura Jeanbart
PDF file - 37K, NPs target the tdLN.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f8cfd87c5e934da3ec9f6b81804dc25
https://doi.org/10.1158/2326-6066.22538818
https://doi.org/10.1158/2326-6066.22538818
Autor:
Melody A. Swartz, Jeffrey A. Hubbell, Pedro Romero, Patricia Corthésy, Alexandre de Titta, Marie Ballester, Laura Jeanbart
PDF file - 51K, NP-conjugated OVA and CpG induces functional OVA257-264-specific CD8+ T cells and antibodies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95f8a1a5cba2f0290e27deb09321c5c7
https://doi.org/10.1158/2326-6066.22538815.v1
https://doi.org/10.1158/2326-6066.22538815.v1
Autor:
Melody A. Swartz, Jeffrey A. Hubbell, Pedro Romero, Patricia Corthésy, Alexandre de Titta, Marie Ballester, Laura Jeanbart
PDF file - 254K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60c1a63a8c7d89356477172a1bf182de
https://doi.org/10.1158/2326-6066.22538800.v1
https://doi.org/10.1158/2326-6066.22538800.v1
Autor:
Melody A. Swartz, Jeffrey A. Hubbell, Pedro Romero, Patricia Corthésy, Alexandre de Titta, Marie Ballester, Laura Jeanbart
The sentinel or tumor-draining lymph node (tdLN) serves as a metastatic niche for many solid tumors and is altered via tumor-derived factors that support tumor progression and metastasis. tdLNs are often removed surgically, and therapeutic vaccines a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ab562323a976a071a13d22902ac8fe
https://doi.org/10.1158/2326-6066.c.6548902.v1
https://doi.org/10.1158/2326-6066.c.6548902.v1
Autor:
Melody A. Swartz, Jeffrey A. Hubbell, Pedro Romero, Patricia Corthésy, Alexandre de Titta, Marie Ballester, Laura Jeanbart
PDF file - 22K, Targeting the tdLN with NP-OVA and NP-CpG induces more antigen-specific and effector CD8+ T cells in the tumor, spleen, and tdLN.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bed0557c06830d8eb07ed79860b6d05
https://doi.org/10.1158/2326-6066.22538809
https://doi.org/10.1158/2326-6066.22538809
Autor:
Melody A. Swartz, Jeffrey A. Hubbell, Pedro Romero, Patricia Corthésy, Alexandre de Titta, Marie Ballester, Laura Jeanbart
PDF file - 42K, CD4+ T cells are more polyfunctional upon ex vivo restimulation when NP-OVA + NP-CpG is targeted to the tdLN.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0183cd2fa2e33b283317951c1ccf96cd
https://doi.org/10.1158/2326-6066.22538806
https://doi.org/10.1158/2326-6066.22538806
Autor:
Jean-François Franetich, Sachiko Hirosue, Maria A. S. Broggi, Giacomo Diaceri, Melody A. Swartz, Xavier Quaglia-Thermes, Marcin Kwissa, Jeffrey A. Hubbell, Dominique Mazier, Leonardo Bonilla-Ramirez, Laura Jeanbart, D. Scott Wilson, Ruyi Wang, Michal M. Raczy
Publikováno v:
Nature Materials. 18:175-185
Fully effective vaccines for complex infections must elicit a diverse repertoire of antibodies (humoral immunity) and CD8+ T-cell responses (cellular immunity). Here, we present a synthetic glyco-adjuvant named p(Man–TLR7), which, when conjugated t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee076d94a592abcf84502db63df7467
https://doi.org/10.1038/s41563-018-0256-5
https://doi.org/10.1038/s41563-018-0256-5
Autor:
Bernd Schlereth, Alexandra Neculcea, Nicole Bassler, Daniel Steiner, Sebastian Grimm, Nina Reschke, Yvonne Gruebler, Thamar Looser, Laura Jeanbart, Jennifer Krieg, Matteo Bianchi, Patricia Schildknecht, Tanja Hospodarsch, Christian Reichen
Publikováno v:
Cancer Research. 81:525-525
Purpose: The medical need due to high mortality in acute myeloid leukemia (AML) remains high, and the treatment of relapsed or refractory AML continues to be therapeutically challenging. MYLOTARG, the only approved anti-CD33 antibody drug conjugate (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::301f9d94f547ba8d3ac30cebed8601ea
https://doi.org/10.1158/1538-7445.am2021-525
https://doi.org/10.1158/1538-7445.am2021-525